Compare TRIB & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRIB | ADVB |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 8.6M |
| IPO Year | 1996 | 2023 |
| Metric | TRIB | ADVB |
|---|---|---|
| Price | $7.47 | $7.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.7K | ★ 203.8K |
| Earning Date | 05-22-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 5.21 |
| Revenue | N/A | N/A |
| Revenue This Year | $13.51 | N/A |
| Revenue Next Year | $13.14 | N/A |
| P/E Ratio | ★ N/A | $1.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.19 |
| 52 Week High | $14.17 | $24.23 |
| Indicator | TRIB | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 35.31 | 45.98 |
| Support Level | $0.55 | $3.95 |
| Resistance Level | $14.03 | $9.50 |
| Average True Range (ATR) | 0.72 | 0.97 |
| MACD | -0.51 | -0.18 |
| Stochastic Oscillator | 10.90 | 18.25 |
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.